These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 15124199)

  • 1. Challenges in the development of high protein concentration formulations.
    Shire SJ; Shahrokh Z; Liu J
    J Pharm Sci; 2004 Jun; 93(6):1390-402. PubMed ID: 15124199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Screening Tools Used in High-Concentration Protein Formulation Development.
    Hofmann M; Gieseler H
    J Pharm Sci; 2018 Mar; 107(3):772-777. PubMed ID: 29102552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized UV detection of high-concentration antibody formulations using high-throughput SE-HPLC.
    Molloy S; Fesinmeyer RM; Martinez T; Piedmonte DM; Pelletier ME; Treuheit MJ; Kleemann GR
    J Pharm Sci; 2015 Feb; 104(2):508-14. PubMed ID: 25392911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions.
    Allmendinger A; Fischer S; Huwyler J; Mahler HC; Schwarb E; Zarraga IE; Mueller R
    Eur J Pharm Biopharm; 2014 Jul; 87(2):318-28. PubMed ID: 24560966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-concentration protein formulations: How high is high?
    Garidel P; Kuhn AB; Schäfer LV; Karow-Zwick AR; Blech M
    Eur J Pharm Biopharm; 2017 Oct; 119():353-360. PubMed ID: 28690199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.
    Brummitt RK; Nesta DP; Roberts CJ
    J Pharm Sci; 2011 Oct; 100(10):4234-43. PubMed ID: 21671226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effect of syringe surfaces on protein formulations.
    Majumdar S; Ford BM; Mar KD; Sullivan VJ; Ulrich RG; D'souza AJ
    J Pharm Sci; 2011 Jul; 100(7):2563-73. PubMed ID: 21319164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration.
    Cole ET; Cadé D; Benameur H
    Adv Drug Deliv Rev; 2008 Mar; 60(6):747-56. PubMed ID: 18096270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and manufacturability of biologics.
    Shire SJ
    Curr Opin Biotechnol; 2009 Dec; 20(6):708-14. PubMed ID: 19880308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Intercompany Perspective on Practical Experiences of Predicting, Optimizing and Analyzing High Concentration Biologic Therapeutic Formulations.
    Desai PG; Garidel P; Gbormittah FO; Kamen DE; Mills BJ; Narasimhan CN; Singh S; Stokes ESE; Walsh ER
    J Pharm Sci; 2023 Feb; 112(2):359-369. PubMed ID: 36442683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of surfaces and leachables on the stability of biopharmaceuticals.
    Bee JS; Randolph TW; Carpenter JF; Bishop SM; Dimitrova MN
    J Pharm Sci; 2011 Oct; 100(10):4158-70. PubMed ID: 21523787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
    Cirri M; Mura P; Mora PC
    Int J Pharm; 2007 Aug; 340(1-2):84-91. PubMed ID: 17531411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dropwise additive manufacturing of pharmaceutical products for melt-based dosage forms.
    Içten E; Giridhar A; Taylor LS; Nagy ZK; Reklaitis GV
    J Pharm Sci; 2015 May; 104(5):1641-9. PubMed ID: 25639605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced protein formulations.
    Wang W
    Protein Sci; 2015 Jul; 24(7):1031-9. PubMed ID: 25858529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microenvironmental pH modulation in solid dosage forms.
    Badawy SI; Hussain MA
    J Pharm Sci; 2007 May; 96(5):948-59. PubMed ID: 17455349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of drug delivery technologies in lead candidate selection and optimization.
    Chaubal MV
    Drug Discov Today; 2004 Jul; 9(14):603-9. PubMed ID: 15239979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability and solubility of trans-resveratrol are strongly influenced by pH and temperature.
    Zupančič Š; Lavrič Z; Kristl J
    Eur J Pharm Biopharm; 2015 Jun; 93():196-204. PubMed ID: 25864442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple method for the detection of insoluble aggregates in protein formulations.
    Li B; Flores J; Corvari V
    J Pharm Sci; 2007 Jul; 96(7):1840-3. PubMed ID: 17299781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.